Toxicity from TKI or mTOR inhibitors for RCC and from chemotherapy, BRAF inhibitors or anti-CTLA-4 antibodies for melanoma are low-grade but continuous and exert a negative impact on quality of life. The gene discussed is BRAF; the disease is melanoma.